Core Viewpoint - Dige Pharmaceutical (688192.SH) expects significant growth in revenue and a reduction in net losses for the fiscal year 2025, indicating a positive outlook for the company's financial performance [1] Financial Performance - The company anticipates a revenue of approximately 800 million yuan for 2025, an increase of about 440.1 million yuan compared to the previous year, representing a year-on-year growth of approximately 122.28% [1] - The projected R&D expenses for 2025 are around 860 million yuan, which is an increase of about 136.31 million yuan from the previous year, reflecting a year-on-year increase of approximately 18.84% [1] Net Losses - The expected net loss attributable to the parent company's shareholders for 2025 is around 770 million yuan, which is a reduction of approximately 75.96 million yuan compared to the previous year, indicating a year-on-year decrease in losses of about 8.98% [1] - The projected net loss attributable to the parent company after excluding non-recurring gains and losses is approximately 850 million yuan, which is a decrease of about 48.89 million yuan from the previous year, showing a year-on-year reduction in losses of approximately 5.44% [1]

Core Viewpoint - The company expects a revenue of approximately 800 million yuan for the fiscal year 2025, representing a year-on-year increase of 122.28%, primarily due to the inclusion of two approved products in the medical insurance and increased promotion efforts [1] Financial Performance - The projected R&D expenses are 860 million yuan, reflecting a year-on-year increase of 18.84%, indicating that the company's ongoing projects are progressing well with multiple clinical data announcements [1] - The expected net loss attributable to the parent company is 770 million yuan, which is a year-on-year decrease of 8.98%, while the net loss after excluding non-recurring items is projected at 850 million yuan, a year-on-year decrease of 5.44% [1] Product Development - The company has made significant progress in its research and development pipeline, with several projects announcing clinical data and some products receiving relevant FDA recognition and commencing clinical studies [1]

Core Viewpoint - The company, Dize (Jiangsu) Pharmaceutical Co., Ltd., is advancing its international capital strategy by approving the issuance of H-shares and plans for listing on the Hong Kong Stock Exchange, marking a significant step in its growth and expansion [1] Group 1: Shareholder Meeting Decisions - The company held its first extraordinary general meeting of 2026 on January 9, where multiple important resolutions were approved [1] - Key decisions included the approval of the H-share issuance plan, amendments to the company’s articles of association, and changes to registered capital to facilitate the listing [1] - The meeting also approved the distribution plan for retained earnings prior to the issuance, the appointment of a listing audit firm, and the establishment of a primary business address in Hong Kong [1] Group 2: Voting and Approval Details - The resolutions were supported by shareholders holding 64.4445% of the total voting rights, with all proposals receiving high approval [1] - Eight resolutions related to the H-share issuance and amendments to the articles of association were passed as special resolutions, each receiving over two-thirds approval from the voting rights present [1] Group 3: Strategic Implications - The decisions made during the shareholder meeting lay a crucial legal and decision-making foundation for the company's Hong Kong listing plan [1] - This marks an important milestone in the company's internationalization efforts and capital strategy [1]

二〇二六年一月 北京市中伦律师事务所 关于迪哲（江苏）医药股份有限公司 2026 年第一次临时股东会的 法律意见书 北京市中伦律师事务所 关于迪哲（江苏）医药股份有限公司 2026 年第一次临时股东会的 法律意见书 致：迪哲（江苏）医药股份有限公司 根据迪哲（江苏）医药股份有限公司（以下简称"公司"）与北京市中伦律 师事务所（以下简称"本所"）签订的《常年法律服务协议》的约定及受本所指 派，本所律师对公司 2026 年第一次临时股东会（以下简称"本次股东会"）的 合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委 员会（以下简称"中国证监会"）《上市公司股东会规则》（以下简称"《股东 会规则》"）等现行有效的有关法律、法规和规范性文件以及《迪哲（江苏）医 药股份有限公司章程》（以下简称"《公司章程》"）的规定而出具。 本所律师根据法律的要求，按照律师行业公认的业务标准、道德规范和勤勉 尽责的精神，对公司所提供的相关文件和有关事实进行了核查和验证，现出具法 律意见如下： 一、本次股东会的召集 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2026-001 迪哲（江苏）医药股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 9 日 （二） 股东会召开的地点：无锡市新吴区新阳路 50 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 97 | | --- | --- | | 普通股股东人数 | 97 | | 2、出席会议的股东所持有的表决权数量 | 297,210,231 | | 普通股股东所持有表决权数量 | 297,210,231 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 64.4445 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.4445 | （四） 表决方式是否符合《公司 ...

Group 1 - The core point of the news is that Dize Pharmaceutical has seen a stock price increase of 5.2%, reaching 66.75 yuan per share, with a total market capitalization of 30.784 billion yuan [1] - Dize Pharmaceutical, established on October 27, 2017, focuses on the research and industrialization of innovative drugs, with 100% of its main business revenue coming from drug sales [1] - The company is located in Wuxi, Jiangsu Province, and has been listed since December 10, 2021 [1] Group 2 - According to data, the Tongtai Health Theme Mixed A Fund (011002) holds 37,600 shares of Dize Pharmaceutical, accounting for 5.41% of the fund's net value, making it the fifth-largest holding [2] - The fund has a total scale of 13.7512 million yuan and has achieved a year-to-date return of 7.74%, ranking 577 out of 8,827 in its category [2] - The fund's one-year return is 25.89%, with a ranking of 4,600 out of 8,084, while it has experienced a cumulative loss of 50.98% since inception [2] Group 3 - The fund managers of Tongtai Health Theme Mixed A are Ma Yi and Mai Jianpei, with Ma Yi having a tenure of 11 years and 299 days and a total fund size of 2.718 billion yuan [3] - During Ma Yi's tenure, the best fund return was 44.72%, while the worst was -7.73% [3] - Mai Jianpei has a tenure of 243 days with a fund size of 231 million yuan, achieving a best return of 23.27% and a worst return of -7.73% during his tenure [3]

Group 1 - The core viewpoint of the news highlights the performance and growth of the Tianhong Innovation Drug ETF (517380), which has seen significant trading activity and net inflows, indicating strong investor interest in the innovative pharmaceutical sector [1] - As of January 8, the Tianhong Innovation Drug ETF reached a new high with a total scale of 1.597 billion yuan and 1.980 billion shares outstanding, reflecting robust market demand [1] - The ETF tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID), which includes a diverse selection of 50 leading innovative pharmaceutical companies, with a composition of 40% Hong Kong stocks and 60% A-shares [1] Group 2 - Notable achievements in the innovative pharmaceutical sector include Shiyao Group's R&D expenses of 4.185 billion yuan for the first three quarters of 2025, focusing on ADC, GLP-1, and small nucleic acid pipelines, with total authorized amounts exceeding 9.7 billion USD [2] - BeiGene is projected to achieve a profit of 200 million USD in 2025, with expectations of reaching 600-800 million USD in 2026, as several solid tumor drugs enter critical clinical stages [2] - Three Life Sciences has partnered with Pfizer for a 6 billion USD dual antibody licensing deal, receiving an upfront payment of 1.4 billion USD, with 20 clinical studies planned for 2026 [2]

Core Insights - In 2025, the FDA approved 46 new drugs, indicating a decline in the number of approvals compared to 2024 and 2023, but the approved drugs are diverse and highly innovative [2][3] Group 1: Drug Approval Overview - The approved new drugs in 2025 are characterized by high innovation, with over half classified as "first-in-class" therapies [3] - The majority of the approved drugs are small molecule drugs, with others including monoclonal antibodies, ADCs, siRNA, ASOs, fusion proteins, and bispecific T-cell engagers [3] Group 2: Therapeutic Areas - Oncology is the predominant therapeutic area for the approved new drugs, covering various solid tumors and hematological malignancies [4] - Other therapeutic areas include respiratory, endocrine and metabolic, and cardiovascular diseases, with 34 of the new drugs undergoing special review processes [4] Group 3: Company Performance - Major multinational pharmaceutical companies such as Merck, Eli Lilly, Boehringer Ingelheim, and GlaxoSmithKline each had two new drugs approved [5] - Domestic companies also achieved approvals, with Zhongshan Kangfang Biopharmaceutical Co., Ltd.'s Paimupili monoclonal antibody and Dize (Jiangsu) Pharmaceutical Co., Ltd.'s Shuwotini receiving FDA approval [5] Group 4: Investment Recommendations - The report suggests focusing on companies with cutting-edge technology platforms, particularly those involved in ADC, siRNA, and cell gene therapy (CGT) [1] - It is recommended to invest in Chinese innovations with global competitiveness, especially those conducting or planning global multi-center clinical trials, and those utilizing a collaboration model where Chinese companies handle early-stage R&D while multinational companies manage later-stage clinical and commercialization efforts [1]

Group 1: Pharmaceutical and Biotech Industry - The pharmaceutical and biotech industry in China is entering a new era of innovative drugs, transitioning from a generics-dominated market (pre-2018) to a focus on innovation from 2026 onwards, with significant growth expected in innovative drug development and commercialization [5] - The report highlights the importance of monitoring the launch rhythm of innovative drugs, competitive landscape, and key clinical data in 2026, as well as the impact of international business development (BD) transactions on cash flow [5] - The CXO and upstream scientific reagent sectors are expected to benefit from the rapid development of innovative drugs, maintaining a strong growth momentum [5] Group 2: Medical Device Industry - The medical device industry has faced significant challenges over the past three years, including anti-corruption measures and price reductions, leading to a decline in profitability for listed companies [6] - However, since 2025, there has been a gradual recovery in the industry, with improved profitability expected in 2026 as negative factors clear and new technologies like brain-computer interfaces and AI products emerge [6] - The overseas market is anticipated to become a new growth point due to companies' investments in capacity, channels, and branding [6] Group 3: Medical Services Consumption - The medical services consumption sector has been under pressure from macroeconomic conditions and policy changes, but is expected to recover as domestic consumption gradually improves [7] - The report emphasizes the potential for specialized hospitals with brand and chain advantages to lead growth in 2026, alongside the retail service market benefiting from the diversification of services [7] - A list of recommended stocks includes companies like Kelun Pharmaceutical, Rongchang Bio, and Yifeng Pharmacy, which are positioned to capitalize on these trends [7] Group 4: Manufacturing PMI Insights - The manufacturing PMI for December 2025 was reported at 50.1%, indicating a recovery from the previous value of 49.2%, driven by improved demand and supply conditions [10][11] - Factors contributing to this increase include positive expectations from recent important meetings, a recovery in trade relations, and increased pre-holiday inventory demands [10][12] - High-tech manufacturing sectors showed significant growth, with the high-tech PMI reaching 52.5%, indicating strong performance in this segment [13] Group 5: Economic Policy and Market Outlook - The central economic work conference has set a positive tone for 2026, emphasizing the importance of domestic demand and investment stabilization [15] - The report suggests that upcoming policies will focus on enhancing consumer spending and investment, with potential adjustments in housing policies expected to support the market [15] - The market is advised to focus on sectors benefiting from technological advancements and domestic consumption trends, particularly in light of anticipated policy support [16]

Market Overview - The Shanghai Composite Index closed at 4023.42 points, above the annual line, with a gain of 1.38% [1] - The total trading volume of A-shares reached 30,483.30 billion yuan [1] Stocks Breaking Annual Line - A total of 204 A-shares have surpassed the annual line today, with notable stocks including: - Guanhao Biological (300238) with a deviation rate of 13.10% - Beilu Pharmaceutical (300016) with a deviation rate of 12.97% - Yinkang Life (300143) with a deviation rate of 12.90% [1] Stocks with Significant Deviation Rates - Stocks with high deviation rates include: - Guanhao Biological: 20.00% increase, latest price at 16.62 yuan - Beilu Pharmaceutical: 13.22% increase, latest price at 8.99 yuan - Yinkang Life: 15.18% increase, latest price at 11.38 yuan [1] Additional Stocks with Positive Performance - Other stocks showing positive performance include: - Gangtong Medical (301515) with a 14.16% increase and a deviation rate of 12.82% - Zhite New Materials (300986) with a 20.04% increase and a deviation rate of 10.50% [1] Stocks with Lower Deviation Rates - Stocks that have just crossed the annual line with lower deviation rates include: - Longqi Technology (603341) with a 10.01% increase and a deviation rate of 9.02% - Taihe New Materials (002254) with a 9.98% increase and a deviation rate of 8.61% [1]